

JAPAN KAMPO MEDICINES MANUFACTURERS ASSOCIATION (JKMA)

日本漢方生薬製剤協会

GUIDE
2018



Message from Chairman



Terukazu Kato
Chairman of JKMA

JKMA is currently conducting cross-functional project activities in response to the recommendations published in March 2017 by “Forum : The Vision for Kampo Medicine and Public Welfare”. Based on the above recommendations, JKMA announced a new forward-looking vision in July 2018, “The Future Vision for Kampo Medicines 2040”.

Moreover, following “4th study Group Conference on the Vision for Kampo Medicine and Public Welfare 2017” in December 2017, JKMA intended to hold “5th study Group Conference on the Vision for Kampo Medicine and Public Welfare 2018” in February 2019, in which some progress made after the recommendations will be reported. We are now planning the contents of the “5th study Group Conference” in collaboration with Recommendation Execution Committee of the Japan Society for Oriental Medicine.

As feedback on drug price revisions and the review of the drug pricing rules, JKMA requested “Inclusion of Kampo products and crude drug products for ethical use in basic drugs” and the “repricing of unprofitable crude drugs.” As a result, in the 2018 drug price revision, the prices of 16 crude drugs were raised through the repricing of unprofitable products and, at the same time, the crude drugs were included in basic drugs. JKMA is grateful that our requests were accepted.

While the crude drugs were newly classified as basic drugs, it was a great shame, however, that Kampo products and crude drug products made from the high-priced crude drugs were not included in basic drugs, and JKMA feels a deep concern from the viewpoint of contribution to people’s health care.

Kampo medicines are considered to be important for health care under Japan’s National Health Insurance system. Actually, 34 Kampo extracts were monographed in “The Japanese Pharmacopoeia XVII” and additional Kampo extracts are still under examination.

But then, Kampo medicines also have many problems from the viewpoint of their sustainable, stable supply. No new Kampo products for ethical use come onto the market for 30 years, and the prices of the crude drugs used are rising, etc. Accordingly, JKMA believes that the inclusion of Kampo products and crude drug products in basic drugs is absolutely essential to maintain a stable supply to patients.

As JKMA considers the inclusion of crude drugs in basic drugs as a first step, we will keep lobbying hard for Kampo products and crude drug products for ethical use to be included in basic drugs, and will continue contributing to people’s health care through their stable supply.

Quality assurance of raw materials for crude drugs and procurement of the necessary quantity at a reasonable price are common challenges faced by all member companies. In terms of price, we need to keep an eye on the impact of rising labor costs and other operating expenses brought about by economic development and expansion in the usage of crude drugs on domestic market in China. At present, we are able to procure the quantities we need, considering the growth of domestic demand in China, the outlook is however far from optimistic situation.

For these reasons, JKMA believes that it is essential to promote and expand domestic production of crude drugs in Japan, and that the MAFF’s “Support Project for Development of Medicinal Crop Cultivating Sources” is an important policy which should continue to be utilized.

Hereafter, JKMA will step up its activities, providing presentations highlighted success stories of medicinal crop cultivating sources, and supporting the trial cultivation of medicinal crops through the dispatch of technical advisors.

Very recently, the Japan Agency for Medical Research and Development (AMED) has proposed a new project aimed at implementing technology for the cultivation of medicinal crops built up in Japan, i. e. “The Project to Promote Domestic Cultivation and Utilization of Medicinal Crops”. This project will be formed by government, academia and private companies, which will collaboratively develop technologies to speed up the domestic cultivation of medicinal crops. JKMA is also supporting the project to have results steadily and to achieve the stable supply of crude drugs.

In recent years, there have been many compliance violations at leading Japanese companies. JKMA has also adopted a policy of focusing on compliance with a sense of urgency to ensure that similar problems do not occur at member companies. In 2017, we conducted a fact-finding survey of compliance at each member company. The survey results are being verified by an outside specialist and we are holding training sessions.

JKMA will continue doing its utmost to contribute to the people’s health and health care. We would be most grateful if you could provide us with your continuous support and understanding.

Business Plan for Fiscal 2018

■ On the Establishment of the Business Plan

JKMA will start our activities under the new vision “The Future Vision for Kampo Medicines 2040”. This vision is revised in light of the recommendations of “Forum : The Vision for Kampo Medicine and Public Welfare” (hereafter Study Group) and by reviewing the former vision of JKMA, “The New Movement for Kampo Medicines in 21st Century”, announced in May 2001. In 2018, we are also faced with the second year of “The 2017 Medium-to-Long-Term Business Plan (Five Year Plan)”. JKMA will challenge to resolve a various problem in collaboration with member companies and the relevant organizations both in Japan and overseas.

To realize the recommendations of Study Forum Group, last year JKMA established the cross-functional project, “Future Vision Project for Kampo Medicines and Public Welfare” (hereafter PJ). PJ is now full activities for the sustainable development of Kampo medicines, including continuously holding Study Group, researching Kampo medicines, establishing evidences, developing application guidelines for Kampo medicines, lobbying government organizations, and so on. Additionally, PJ also renewed JKMA’s website in order to patient awareness-raising as part of outreach activities, and continue working to ensure that information about JKMA activities and Kampo medicines is understood correctly.

Japan relies on imports of crude drugs from China to meet around 80% of its needs. Therefore, JKMA will also focus on the promotion of domestic cultivation under the leadership of “The Medicinal Crop Production Region Support Council “ established jointly with “Japan Agricultural Development and Extension Association” as part of the MAFF-subsidized “The Support Project for Development of Medicinal Crop Cultivating Sources”. Last year, JKMA gave a presentation on the results of a survey about the prices of crude drugs produced in Japan and those produced in China. This data was received from domestic producers saying they found the presentation very useful.

“Comprehensive Drug Industry Reinforcement Strategy” revised last year states that the government will implement initiatives to promote domestic cultivation of medicinal crops. Also they provide support for research new cultivation/production technologies to seek to diversify the sources of supply of crude drugs, which play an important role in health care in Japan. JKMA will continue to lobby relevant organizations to provide more extensive support.

Last year, there were compliance violations by many leading Japanese companies. JKMA also needs to focus on compliance with a sense of urgency. We will verify the results of the survey about the compliance framework conducted last year, and provide useful training sessions for member companies. JKMA will continue to take action for the establishment of a compliance framework. We will also work to raise awareness of compliance including compliance with JKMA’s voluntary standards such as “The JKMA Code of Practice “revised last year and disclosure based on our “Transparency Guidelines”.

In 2018, JKMA will collaborate closely with our members to achieve the reliable supply of high-quality Kampo medicines and seek to make Kampo medicines more widely used, thereby contributing to public health and the development of the pharmaceutical industry.

JKMA Outline

Established

Japan Kampo Medicines Manufacturers Association (JKMA) was established on July 21, 1983 by domestic manufacturers and distributors (including importers) of Kampo products and crude drug products derived from crude drug, as well as other businesses associated with raw materials for crude drug.

Aims


Based on close cooperation among its members, JKMA provides continuous and stable supply of high-quality Kampo formulation, crude drug formulation, and crude drug. By enhancing its roles and functions, JKMA aims to contribute to the growth of the pharmaceutical industry and the health of the nation by disseminating, embedding and developing Kampo formulation, crude drug formulation, and crude drug.

Present Situation

As an industrial body, JKMA is affiliated with the Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ), an organization representing all pharmaceutical industries in Japan.

As of November 1, 2018, JKMA has 64 member companies.

Related Organizations



Business Policies for Fiscal 2017

1. Reliable procurement of raw materials for crude drugs

2. Overall quality assurance from raw materials for crude drugs to finished products


3. International correspondence for Kampo medicines, etc.

4. Development and nourishment of Kampo medicines, etc.

5. Promotion of awareness-raising activities and communication for various stakeholders

6. Enhancement of JKMA activities

Organization of JKMA



Introduction of Commissions and Committees

Business Ethics Committee

Centered on top management in member companies, and newly established in April 2011 to meet social responsibilities based on compliance with laws and ordinances and a high sense of ethics.



Chairman
Terukazu Kato, Tsumura & Co.

Ethical Kampo Products Commission

Ethical Kampo Products Commission consists of 12 member companies handling ethical Kampo formulation and its bulk extracts.



Chairman
Terukazu Kato, Tsumura & Co.



Ethical Kampo Products Committee
Chairman
Hisashi Hasegawa, Tsumura & Co.

Subcommittee for Promoting Proper Usage
Head
Hiroyuki Matsuzuka, Kracie Pharmaceutical, Ltd.

Usability Research Subcommittee
Head
Miyuki Minari, Tsumura & Co.

Education and Training Subcommittee
Head
Katsuaki Yoshida, Tsumura & Co.

Introduction of Commissions and Committees

Crude Drugs Commission

Crude Drugs Commission consists of 29 member companies handling raw materials for crude drug (captive consumption, sales), and companies handling crude drug for dispensing and other final products.



Chairman
Hideki Yoshikawa, Uchida Wakanyaku Ltd.



Crude Drugs Committee
Chairman
Makoto Shiratori, Uchida Wakanyaku Ltd.

Team for Domestic Crude Drug Production
Head
Hirokazu Koyanagi, Tsumura & Co.

Crude Drug Project Subcommittee
Head
Hiroshi Sasaki, Nippon Funmatsu Yakuhin Co., Ltd.

Crude Drug Cultivation Subcommittee
Head
Osami Takeda, Tsumura & Co.

Crude Drug Distribution Subcommittee
Head
Yutaka Yamamoto, Tochimoto Tenkaido Co., Ltd.

OTC Kampo Products Commission

OTC Kampo Products Commission consists of 38 member companies handling OTC Kampo formulation.



Chairman
Yoichi Nakashima, Kracie Pharmaceutical, Ltd.



OTC Kampo Products Committee
Chairman
Yoshiaki Nagashima, Kracie Pharmaceutical, Ltd.

Prescription Subcommittee
Head
Kikumi Takahashi, Tsumura & Co.

Subcommittee for Promoting Proper Usage
Deputy Head
Yoshiaki Nagashima, Kracie Pharmaceutical, Ltd.

Introduction of Commissions and Committees

Crude Drug Products Commission

Crude Drug Products Commission consists of 27 member companies handling crude drug formulation.



Chairman
Yutaka Kobayashi, Kobayashi Pharmaceutical Co., Ltd.



Crude Drug Products Committee
Chairman
Atsunori Wada, Kobayashi Pharmaceutical Co., Ltd.

System Research Subcommittee

Formulation Development Subcommittee
Head
Kenichi Wakabayashi, Kobayashi Pharmaceutical Co., Ltd.

Bulk Extracts Commission

Bulk Extracts Commission consists of 5 member companies manufacturing all types of extracts such as tinctures, dry extracts and so on.



Chairman
Shoichi Kuwano, Nippon Funmatsu Yakuhin Co., Ltd.



Bulk Extracts Committee
Chairman
Hiroshi Sasaki, Nippon Funmatsu Yakuhin Co., Ltd.

General Affairs Committee



Chairman
Shingo Takeshita, Tsumura & Co.

General Affairs Subcommittee
Head
Shingo Takeshita, Tsumura & Co.

Project Subcommittee
Head
Ryozo Matsumoto, Kotaro Pharmaceutical Co., Ltd.

Environmental Subcommittee
Head
Takashi Kanno, JPS Pharmaceutical Co., Ltd.

Introduction of Commissions and Committees

Public Relations Committee



Chairman
Yousuke Tsuchiya, Tsumura & Co.

Web Project Subcommittee
Head
Minoru Nakajima, Tsumura & Co.

International Committee



Chairman
Takashi Morota, Tsumura & Co.

Pharmaceutical Regulations Committee



Chairman
Hirokazu Kurita, Kracie Pharmaceutical, Ltd.

Technical Committee



Chairman
Takashi Furuya, Tsumura & Co.

Test Method Subcommittee
Head
Seizo Kondo, Kotaro Pharmaceutical Co., Ltd.

Impurity Test Method Subcommittee
Head
Hidehiro Ando, Kotaro Pharmaceutical Co., Ltd.

Technical Quality Subcommittee
Head
Yasuhiro Takasugi, Tsumura & Co.

Crude Drug Quality Subcommittee
Head
Tsuguo Yokokura, Nippon Funmatsu Yakuhin Co., Ltd.

Introduction of Commissions and Committees

Safety Committee



Chairman
Masanori Katori, Tsumura & Co.

Drugs Consultation Subcommittee
Head
Keiji Mori, Kotaro Pharmaceutical Co., Ltd.

Reevaluation Subcommittee
Head
Masanori Katori, Tsumura & Co.

Code Review Board

Code Review Board consists of 5 member companies participating in the Ethical Kampo Products Commission and the Crude Drugs Commission, in order to implement the Promotion Code for ethical Kampo formulation and crude drug.



Representative Member
Hiroyuki Matsuzuka, Kracie Pharmaceutical, Ltd.

Subcommittee for Product Information Summary
Head
Toshihiro Yamamura, Tsumura & Co.

NHI Pricing committee

The purpose of the NHI Pricing Committee is to contribute to the improvement of national medical care by ensuring the sustainable growth of ethical kampo formulations and crude drugs within systems such as medical insurance and the NHI drug price standard. The NHI Pricing Committee consists of 15 member companies.



Chairman
Makoto Sakaue, Tsumura & Co.

NHI Pricing Subcommittee
Head
Fumito Yanagisawa, Tsumura & Co.

Future Vision Project for Kampo Medicines and Public Welfare



Leader
Makoto Sakaue, Tsumura & Co.

Board of Directors

Title	Name	Company	Company position
Chairman	Terukazu Kato	Tsumura & Co.	President, Representative Director
Vice-chairman	Yutaka Kobayashi	Kobayashi Pharmaceutical Co., Ltd.	Vice chairman
ditto	Ippei Suzuki	Kotaro Pharmaceutical Co., Ltd.	President and Representative Director
ditto	Yoichi Nakashima	Kracie Pharmaceutical, Ltd.	Representative Director and Chairman
ditto	Shoichi Kuwano	Nippon Funmatsu Yakuhin Co., Ltd.	President and Representative Director
ditto	Hideki Yoshikawa	Uchida Wakanyaku Ltd.	President and Representative Director
Managing Director	Yoshio Machida	Japan Kampo Medicines Manufacturers Association	
Director	Osamu Ushimaru	Alps Pharmaceutical Ind. Co., Ltd.	Representative Director
ditto	Masaki Mizuno	Asgen Pharmaceutical Co., Ltd.	President and Representative Director
ditto	Yoshiki Nishii	Daiichi Sankyo Healthcare Co., Ltd.	President and Representative Director
ditto	Takehiko Asayama	Honso Pharmaceutical Co., Ltd.	President
ditto	Seiji Kobayashi	JPS Pharmaceutical Co., Ltd.	President and Representative Director
ditto	Masanori Hori	Kyushin Pharmaceutical Co., Ltd.	President and Representative Director
ditto	Yoshiichi Iwamoto	Nissui Pharma Medical Sales Co., Ltd.	President & CEO
ditto	Yoshiaki Ohta	Ohta's Isan Co., Ltd.	President and Representative Director
ditto	Masao Tsuji	Ominedo Pharmaceutical Industry Co., Ltd.	President and Representative Director
ditto	Kunio Yamada	Rohto Pharmaceutical Co., Ltd.	Chairman(CEO) and President
ditto	Ryuta Fujii	Ryukakusan Co., Ltd.	President and Representative Director
ditto	Katsuyoshi Sakamoto	Sakamoto Kampo Pharmaceutical Inc.	Chairman, President and Representative Director
ditto	Koichi Watanabe	Sampo Pharmaceutical Co., Ltd.	President and Representative Director
ditto	Mitsuo Murayama	Sanwa Shoyaku Co., Ltd.	President and Representative Director
ditto	Seiichi Sato	Sato Pharmaceutical Co., Ltd.	President and Representative Director
ditto	Takashi Shibata	Taiko Pharmaceutical Co., Ltd.	President and Representative Director
ditto	Akira Uehara	Taisho Pharmaceutical Co., Ltd.	Chairman
ditto	Mari Nogami	Takeda Consumer Healthcare Company Limited	President
ditto	Yoshitake Tatebayashi	Tatebayashi Shokakudo Co., Ltd.	President and Representative Director
ditto	Daisuke Tochimoto	Tochimoto Tenkaido Co., Ltd.	President and Representative Director

Board of Directors

Title	Name	Company	Company position
Director	Yoshikatsu Yokote	Wakanyaku Medical Institute Ltd.	President and Representative Director
ditto	Kanji Wakunaga	Wakunaga Pharmaceutical Co., Ltd.	President and Representative Director
ditto	Taro Shiozawa	Yomeishu Seizo Co., Ltd.	President and Representative Director
ditto	Kunio Takahashi	Zaiseido Pharmaceutical Co., Ltd.	President and Representative Director
ditto	Sachiaki Ibe	Zeria Pharmaceutical Co., Ltd.	President and Representative Director
Auditor	Tadahiro Matsunaga	Matsuura Yakugyo Co., Ltd.	President and Representative Director
ditto	Takashi Okusa	Ohkusa Yakuhin Co., Ltd.	President and Representative Director
ditto	Takahiro Ueda	Teikoku Kampo Seiyaku Co., Ltd.	President and Representative Director
Senior Executive Advisor	Hachizaemon Kazama	Tsumura & Co.	Former Chairman, JKMA
Advisor	Hidetoshi Imaizumi	Daiichi Sankyo Healthcare Co., Ltd.	Former Vice-chairman, JKMA
ditto	Yasuto Mitani	Kanebo Pharmaceutical Co., Ltd.	Former Chairman, JKMA
ditto	Shigeki Onishi	Kracie Pharmaceutical, Ltd.	Former Vice-chairman, JKMA
ditto	Hiroshi Ozawa	Kracie Pharmaceutical, Ltd.	Former Vice-chairman, JKMA
ditto	Masao Onishi	Kotaro Pharmaceutical Co., Ltd.	Previous Vice-chairman, JKMA
ditto	Kikuhiko Watanabe	Japan Kampo Medicines Manufacturers Association	Previous Managing Director
Secretary-general	Izuru Ogawa	Japan Kampo Medicines Manufacturers Association	

* Alphabetical order of company name.

* For Senior Executive Advisor and Advisors, the company name is shown at the time of their retirement.

Member Companies

Company	Address
Alps Pharmaceutical Ind. Co., Ltd.	2-10-50 Mukai-machi, Furukawa-cho, Hida-city, Gifu 509-4241
Amari Soice Co., Ltd.	13-295 Sinmachi, Husimi-ku, Kyoto 612-8081
Asgen Pharmaceutical Co., Ltd.	2008 Azakobora, Yamada-cho, Mizunami-shi, Gifu 509-6104
Co. Sugihara Tatuji Shoten	2-7-10 Kameido, Koto-ku, Tokyo 136-0071
Daiichi Sankyo Healthcare Co., Ltd.	3-14-10 Nihonbashi-cho, Chuo-ku, Tokyo 103-8234
Daiko Shoyaku Co., Ltd.	1-5-12 Shoken, Chikusa-ku, Nagoya 464-0084
Fukuda Shoten	477 Abeshinmachi, Sakurai-city, Nara 633-0054
Hino Pharmaceutical Co., Ltd.	2-3-15 Doshomachi, Chuo-ku, Osaka 541-0045
Honso Pharmaceutical Co., Ltd.	125 Furukawa-cho, Tenpaku-ku, Nagoya 468-0046
Ichigen Pharmaceutical Co., Ltd.	3-4-10 Kaname-cho, Toshima-ku, Tokyo 171-0043
Iskra Industry Co., Ltd.	1-14-2 Nihonbashi, Chuo-ku, Tokyo 103-0027
JPS Pharmaceutical Co., Ltd.	4-42-22 Higashiyamata, Tsuzuki-ku, Yokohama 224-0023
Kitanihon Pharmaceutical Co., Ltd.	55 Wakasugi, Kamiichimachi, Nakaniikawa-gun, Toyama 930-0314
Kobayashi Pharmaceutical Co., Ltd.	4-4-10 Doshomachi, Chou-ku, Osaka 541-0045
Konishi Pharmaceutical Co., Ltd.	2-33-11 Kamiishikiri-cho, Higashiosaka-city, Osaka 579-8012
Kotaro Pharmaceutical Co., Ltd.	2-5-23 Nakatsu, Kita-ku, Osaka 531-0071
Kowa Company. Ltd.	4-14 Nihonbashi-honcho 3chome, Chuo-ku, Tokyo 103-0023
Kracie Pharmaceutical Co., Ltd.	3-20-20 Kaigan, Minato-ku, Tokyo 108-8080
Kyushin Pharmaceutical Co., Ltd.	1-21-7 Wada, Suginami-ku, Tokyo 166-8533
Matsuura Yakugyo Co., Ltd.	24-21 Enjo-cho, Showa-ku, Nagoya 466-0054
Melsmon Pharmaceutical Co., Ltd.	2-35-6 Higashiryouke, Kawaguchi-city, Saitama 332-0003
Mikuni & Co., Ltd.	2-4-10 Doshomachi, Chuo-ku, Osaka 541-0045
Naganoken Materia Medica Co., Ltd.	879-2 Onbegawa, Sinonoi, Nagano-city, Nagano 388-8006
Naganoken Pharmaceutical Co., Ltd.	100-1 Outakimura, Kiso-gun, Nagano 397-0201
Nippon Funmatsu Yakuhin Co., Ltd.	2-5-11 Doshomachi, Chuo-ku, Osaka 541-0045
Nippon Shinyaku Co., Ltd.	14 Nishinoshomonguchi-cho, Kisshoin, Minami-ku, Kyoto 601-8550
Nissui Pharma Medical Sales Co., Ltd.	1-18-11 Ueno, Taito-ku, Tokyo 110-0005
Nitto Pharmaceutical Industries, Ltd.	35-3 Minamibiraki, Kamiueno-cho, Muko, Kyoto 617-0006
Ohki Pharmaceutical Co., Ltd.	3-3 Kandakaji-cho, Chiyoda-ku, Tokyo 101-0045
Ohkusa Pharmaceutical Co., Ltd.	1-17-15 Morisaki, Yokosuka, Kanagawa 238-0023

Member Companies

Company	Address
Ohsugi Pharmaceutical Co., Ltd.	1-1-2 Tennoji-cho, Minami, Abeno-ku, Osaka 545-0002
Ohta's Isan Co., Ltd.	2-3-2 Sengoku, Bunkyo-ku, Tokyo 112-0011
Ominedo Pharmaceutical Co., Ltd.	574 Nenarigaki, Yamatotakada-city, Nara 635-0051
Rohto Pharmaceutical Co., Ltd.	1-8-1 Tatsuminishi, Ikuno-ku, Osaka 544-8666
Ryukakusan Co., Ltd.	2-5-12 Higashikanda, Chiyoda-ku, Tokyo 101-0031
Sakamoto Kampow Pharmaceutical Inc.	1-5-12 Meishin-cho, Amagasaki-city, Hyogo 661-0021
Sampo Pharmaceutical Co., Ltd.	2-3-18 Shimoochiai, Shinjuku-ku, Tokyo 161-8541
Sankei Seiyaku Co., Ltd.	3-10-14 Ikegami Ota-ku, Toukyo 146-0082
Sanwa Shoyaku Co., Ltd.	6-1 Hiraide-Kogyo-Danchi, Utsunomiya-city, Tochigi 321-0905
Sato Pharmaceutical Co., Ltd.	1-5-27 Motoakasaka, Minato-ku, Tokyo 107-0051
Shinihonseiyaku Co., Ltd.	1-4-7 Otemon, Chuo-ku, Fukuoka 810-0074
Shinsei Pharmaceutical Industry Co., Ltd.	1269 Shimizutani, Takatori-cho, Takaichi-gun, Nara 635-0103
Taiko Pharmaceutical Co., Ltd.	3-34-14 Uchihonmachi, Suita-city, Osaka 564-0032
Taikoseido Pharmaceutical Co., Ltd.	2-1-27 Azuma-dori, Chuo-ku, Kobe 651-0076
Taisho Pharmaceutical Co., Ltd.	3-24-1 Takada, Toshima-ku, Tokyo 170-8633
Takeda Consumer Healthcare Company Limited.	1-8-2 Marunouchi, Chiyoda-ku, Tokyo 100-0005
TK Pharmaceutical Co., Ltd.	2-623-1 Horinouchi-cho, Ohmiya-ku, Saitama 330-0804
Tatebayashi Shokakudo Co., Ltd.	4-3-1 Higashiueno, Taito-ku, Tokyo 110-0015
Teikoku Kampo Seiyaku Co., Ltd.	636-1 Minato, Higashikagawa-city, Kagawa 769-2701
Tochimoto Tenkaido Co., Ltd.	3-21 Suehiro-cho, Kita-ku, Osaka 530-0053
Tohtohshu Seizo Co., Ltd.	6 Tenjin-cho, Shinjuku-ku, Tokyo 162-0826
Tokiwa Pharmaceutical Co., Ltd.	158 Kinoko, Sakura-shi, Chiba 285-0801
Toyo Yakuko Co., Ltd.	6-19-7 Hongo, Bunkyo-ku, Tokyo 113-0033
Tsumura & Co.	2-17-11 Akasaka, Minato-ku, Tokyo 107-8521
Uchida Wakanyaku Ltd.	4-3-3 Higashi-Nippori, Arakawa-ku, Tokyo 116-8571
Wakanyaku Medical Institute Ltd.	1-29-8 Shinjuku, Shinjuku-ku, Tokyo 160-0022
Wakunaga Pharmaceutical Co., Ltd.	4-5-36 Miyahara, Yodogawa-ku, Osaka 532-0003
Yamada Yakken Co., Ltd.	4-1-19 Hishiyaniishi, Higashiosaka-city, Osaka 577-0807
Yamamoto Kanpoh Seiyaku Co., Ltd.	156 Takihigashimachi, Komaki-city, Aichi 485-0035
Yatsume Seiyaku Co., Ltd.	2-14-14 Funabori, Edogawa-ku, Tokyo 134-0091
Yomeishu Seizo Co., Ltd.	16-25 Nanpeidai-cho, Shibuya-ku, Tokyo 150-8563
Zaiseido Pharmaceutical Co., Ltd.	8-31 Oda 2-chome, Wakayama-city Wakayama 640-8323
Zenyaku Kogyo Co., Ltd.	5-6-15 Otsuka, Bunkyo-ku, Tokyo 112-8650
Zeria Pharmaceutical Co., Ltd.	10-11 Nihonbashikobuna-cho, Chuo-ku, Tokyo 103-8351

* Alphabetical order of company name.